Results 101 to 110 of about 1,075,882 (382)

Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines

Cancer Medicine
Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of ...
Expert Panel Management of Peritoneal Carcinomatosis, Timothy Kennedy, Sareena Singh, Gerard Abood, Eric Christenson, Christopher J. Anker, Dmitriy Akselrod, Christopher L. Hallemeier, Krishan R. Jethwa, Ed Kim, Percy Lee, Eric D. Miller, Neil B. Newman, J. Eva Selfridge, Navesh Sharma, William Small Jr, Leila Tchelebi, Vonetta M. Williams, Suzanne Russo   +18 more
doaj   +1 more source

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]

, 2017
Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe, Awada, Ahmad, Brayer, Jason B, Catala, Gaetan, Davila, Marco L, Gilham, David E, Hendlisz, Alain, Kerre, Tessa, Lehmann, Frederic F, Lonez, Caroline, Machiels, Jean-Pascal H, Odunsi, Kunle, Piette, Fanny, Sallman, David A, Van den Neste, Eric, Verma, Bikash   +15 more
core   +1 more source

Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Extracellular vesicle (EV)‐packaged CDC37 are released from TMBhiCTLlo breast cancer cells with high CDC37 expression, and internalized into endo/phagosomes of dendritic cells (DCs). Within these compartments, CDC37 locked HSP90–antigen complex, preventing antigen release into the cytosol.
Ruxin Wang, Yunyi Zhang, Xiangyu Meng, Jianli Zhao, Yue Xing, Qian Ouyang, Ning Zhang, Huiping Chen, Nanyan Miao, Erwei Song, Di Huang   +10 more
wiley   +1 more source

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. [PDF]

, 2017
Relapsed osteosarcoma is a recalcitrant tumor. A patient's cisplatinum (CDDP)-resistant relapsed osteosarcoma lung metastasis was previously established orthotopically in the distal femur of mice to establish a patient-derived orthotopic xenograft (PDOX)
Dry, Sarah M., Eckardt, Mark A., Eilber, Fritz C., Elliott, Irmina A., Hayashi, Katsuhiro, Hoffman, Robert M., Igarashi, Kentaro, Kawaguchi, Kei, Kimura, Hiroaki, Kiyuna, Tasuku, Li, Yunfeng, Miwa, Shinji, Miyake, Kentaro, Miyake, Masuyo, Nelson, Scott D., Russell, Tara A., Singh, Arun S., Tsuchiya, Hiroyuki, Yamamoto, Norio, 三輪, 真嗣, 五十嵐, 健太郎, 土屋, 弘行, 山本, 憲男, 林, 克洋   +23 more
core   +1 more source

Ovarialkarzinom: Chemotherapie intraperitoneal? [PDF]

Im Focus Onkologie, 2015
Die intraperitoneale Applikation der Chemotherapie bei fortgeschrittenem Ovarialkarzinom wird nicht routinemasig eingesetzt. Anhand gepoolter Daten der GOG (Gynecologic Oncology Group) wurde der Langzeiterfolg uberpruft.
openaire   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Icaritin Ameliorates Cisplatin‐Induced Mitochondrial Metabolic Dysfunction‐Associated Nephrotoxicity and Synergistically Potentiates Its Antitumor Efficacy

Advanced Science, EarlyView.
In this study, scRNA‐seq and chemoproteomics are integrated to characterize CDDP‐bound proteins at single‐cell resolution in tumor‐bearing mice. Additionally, the research demonstrates that ICA alleviates CDDP‐induced nephrotoxicity while enhancing its chemotherapeutic efficacy.
Piao Luo, Junhui Chen, Yehai An, Kun Meng, Wei Zhou, Wenhui Li, Jing Liu, Wentong Zhao, Weiyi He, Ting Cao, Jingnan Huang, Sha Feng, Shiguang Yang, Hongling Hu, Jiaxian Liao, Hengkai He, Mingjing Hao, Qian Zhang, Jigang Wang, Yue Gao   +19 more
wiley   +1 more source

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. [PDF]

, 2017
In the present study, we evaluated the efficacy of trabectedin (TRAB) and temozolomide (TEM) compared to cisplatinum (CDDP) on a patient-derived orthotopic xenogrraft (PDOX) of a lung-metastasis from an osteosarcoma of a patient who failed CDDP therapy ...
Dry, Sarah M, Eilber, Fritz C, Elliott, Irmina, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Miyake, Kentaro, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Singh, Arun S, Tsuchiya, Hiroyuki, Yanagawa, Jane, Zhang, Yong   +15 more
core   +1 more source

Laparoscopic Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Surface Malignancies (PSM): Italian PSM Oncoteam Evidence and Literature Review [PDF]

, 2022
Antonio Sommariva, Mario Valle, Roberta Gelmini, Marco Tonello, Fabio Carboni, Giovanni De Manzoni, Lorena Sorrentino, Enrico Maria Pasqual, Stefano Bacchetti, C. Sassaroli, Andrea Di Giorgio, Massimo Framarini, Daniele Marrelli, Francesco Casella, Orietta Federici   +14 more
openalex   +1 more source

Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)

Pleura and Peritoneum, 2019
Background Peritoneal metastasis (PM) develop in more than 50 % of gastric cancer (GC) patients. Median survival without treatment is not more than 3–7 months, and 8–12 months after modern combination chemotherapy.
V. Khomyakov, A. Ryabov, A. Ivanov, L. Bolotina, A. Utkina, N. Volchenko, Andrey Kaprin   +6 more
semanticscholar   +1 more source